細胞毒性藥物市場 - 按類型、藥物類別、給藥途徑、應用、配銷通路- 全球預測 2024 - 2032

細胞毒性藥物市場規模預計在 2024 年至 2032 年間複合年成長率為 5.4%。據世界衛生組織稱，僅 2022 年，全球估計新增癌症病例 2,000 萬例。在癌症治療中擴大採用細胞毒性藥物將對市場成長軌跡產生積極影響。藥物開發和個人化醫療的重大進步也提高了細胞毒性藥物的功效和安全性。

專注於新型細胞毒性藥物製劑和聯合療法的不斷擴大的研發活動正在增加這些藥物的吸引力。醫療保健支出的增加、醫療保健基礎設施的改善以及對癌症篩檢和治療選擇的認知不斷提高是鼓勵產品採用的其他因素。

細胞毒性藥物產業分為類型、藥物類別、給藥途徑、應用、配銷通路和區域。

根據類型，從 2024 年到 2032 年，學名藥領域的市場規模預計將以 6% 的複合年成長率成長。對負擔得起的癌症治療的需求不斷成長以及學名藥公司不斷擴大的市場滲透率也推動了該細分市場的成長。

按藥物類別分類，由於植物源抗癌藥物的廣泛可用性和已被證實的功效，預計到 2032 年，植物生物鹼領域的細胞毒性藥物市場將以 4.9% 的成長率成長。植物生物鹼，例如長春花生物鹼和紫杉烷，對癌細胞表現出強大的細胞毒活性，使其成為化療方案不可或缺的組成部分。正在進行的旨在發現具有抗癌特性的新型植物源化合物的研究也有助於該領域的擴張。

從地區來看，由於癌症盛行率不斷上升，預計到 2032 年，歐洲細胞毒性藥物產業將大幅成長。藥物開發和個人化醫療的重大進步以及政府的支持政策正在促進癌症研究和治療。不斷成長的醫療支出和不斷改善的醫療基礎設施正在加速細胞毒性藥物的採用。此外，主要市場參與者的存在以及製藥公司和研究機構之間的合作將推動區域產業的擴張。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 全球癌症盛行率不斷上升
    • 藥物開發的技術進步
    • 老年人口不斷增加
    • 聯合療法的採用率不斷上升
  • 產業陷阱與挑戰
    • 藥物開發成本高
    • 不良反應和毒性
• 成長潛力分析
• 監管環境
• 技術景觀
• 波特的分析
• PESTEL分析
• 報銷場景
• 未來市場趨勢
• 缺口分析

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 公司市佔率分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按類型，2018 - 2032

• 主要趨勢
• 品牌藥
• 學名藥

第 6 章：市場估計與預測：按藥物類別，2018 - 2032 年

• 主要趨勢
• 抗代謝藥
• 抗腫瘤抗生素
• 植物生物鹼
• 烷基化劑
• 其他藥物類別

第 7 章：市場估計與預測：按管理途徑，2018 年 - 2032 年

• 主要趨勢
• 口服
• 注射用

第 8 章：市場估計與預測：按應用分類，2018 年 - 2032 年

• 主要趨勢
• 腫瘤學
• 類風濕關節炎
• 多發性硬化症
• 其他應用

第 9 章：市場估計與預測：按配銷通路分類，2018 年 - 2032 年

• 主要趨勢
• 醫院藥房
• 零售藥局
• 網路藥局

第 10 章：市場估計與預測：按地區，2018 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 沙烏地阿拉伯
  • 南非
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 11 章：公司簡介

• Amgen Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Fresenius Kabi AG
• Merck & Co., Inc.
• Novartis AG
• Pfizer, Inc.
• Sanofi
• Teva Pharmaceutical Industries Ltd.

Cytotoxic Drugs Market size is estimated to depict 5.4% CAGR between 2024 and 2032. The increasing incidence of cancer worldwide is fueling the demand for cytotoxic drugs as primary or adjunctive therapies. According to WHO, in 2022 alone, the world witnessed an estimated 20 million new cancer cases. Increasing adoption of cytotoxic drugs in the treatment of cancer will positively influence the market growth trajectory. Significant advancements in drug development and personalized medicine are also enhancing the efficacy and safety profiles of cytotoxic agents.

The expanding R&D activities focused on novel cytotoxic drug formulations and combination therapies are increasing appeal of these drugs. The rising healthcare expenditure, improving healthcare infrastructure, and growing awareness about cancer screening and treatment options are other factors encouraging the product adoption.

The cytotoxic drugs industry is categorized into type, drug class, route of administration, application, distribution channel, and region.

Based on type, the market size from the generic drugs segment is estimated to grow at 6% CAGR from 2024 to 2032. The expiration of patents for branded cytotoxic medications is leading to the availability of cost-effective generic alternatives. The increasing demand for affordable cancer treatments and the expanding market penetration of generic pharmaceutical companies are also driving the segment growth ahead.

By drug class, the cytotoxic drugs market from the plant alkaloids segment is estimated to rise at 4.9% growth rate through 2032, owing to the wide availability and proven efficacy of plant-derived anticancer agents. Plant alkaloids, such as vinca alkaloids and taxanes, exhibit potent cytotoxic activity against cancer cells, making them integral components of chemotherapy regimens. The ongoing research aimed at discovering new plant-derived compounds with anticancer properties is also contributing to the segment expansion.

Regionally, the Europe cytotoxic drugs industry is projected to witness substantial gains by 2032, on account of the increasing prevalence of cancer. Significant advancements in drug development and personalized medicine, and supportive government policies are promoting cancer research and treatment. The rising healthcare expenditure and improving healthcare infrastructure are accelerating the adoption of cytotoxic drugs. Moreover, the presence of key market players and collaborations between pharmaceutical companies and research institutions will fuel the regional industry expansion.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast calculations
• 1.5 Data sources
  • 1.5.1 Primary
  • 1.5.2 Secondary
    • 1.5.2.1 Paid sources
    • 1.5.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of cancer worldwide
    • 3.2.1.2 Technological advancements in drug development
    • 3.2.1.3 Growing geriatric population
    • 3.2.1.4 Rising adoption of combination therapies
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High development costs of drugs
    • 3.2.2.2 Adverse effects and toxicity
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis
• 3.8 Reimbursement scenario
• 3.9 Future market trends
• 3.10 Gap analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Branded drugs
• 5.3 Generic drugs

Chapter 6 Market Estimates and Forecast, By Drug Class, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Antimetabolites
• 6.3 Antitumor antibiotics
• 6.4 Plant alkaloids
• 6.5 Alkylating agents
• 6.6 Other drug classes

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Parenteral

Chapter 8 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Oncology
• 8.3 Rheumatoid arthritis
• 8.4 Multiple sclerosis
• 8.5 Other applications

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospital pharmacies
• 9.3 Retail pharmacies
• 9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Italy
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
  • 10.5.4 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Amgen Inc.
• 11.2 Bristol-Myers Squibb Company
• 11.3 Eli Lilly and Company
• 11.4 F. Hoffmann-La Roche Ltd.
• 11.5 Fresenius Kabi AG
• 11.6 Merck & Co., Inc.
• 11.7 Novartis AG
• 11.8 Pfizer, Inc.
• 11.9 Sanofi
• 11.10 Teva Pharmaceutical Industries Ltd.